Tags

Type your tag names separated by a space and hit enter

A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Curr Med Res Opin. 1981; 7(6):374-83.CM

Abstract

A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis. Twenty-one hospitalized patients with stable spasticity participated in the 6-week trial. Eleven received tizanidine and 10 baclofen in gradually increasing daily doses. The optimal daily dose of tizanidine was between 8 and 36 mg and that of baclofen between 10 and 80 mg. Overall spastic state, spasms and clonus were similarly improved with both medications. In contrast, muscle strength, bladder function and the activities of daily living were more improved on tizanidine than on baclofen. Tiredness was the most frequent side-effect on tizanidine and muscle weakness on baclofen. The laboratory tests did not show any pathological changes with either medication. According to these results, tizanidine provides a new therapeutic alternative in the treatment of spasticity.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7016449

Citation

Smolenski, C, et al. "A Double-blind Comparative Trial of New Muscle Relaxant, Tizanidine (DS 103-282), and Baclofen in the Treatment of Chronic Spasticity in Multiple Sclerosis." Current Medical Research and Opinion, vol. 7, no. 6, 1981, pp. 374-83.
Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin. 1981;7(6):374-83.
Smolenski, C., Muff, S., & Smolenski-Kautz, S. (1981). A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Current Medical Research and Opinion, 7(6), 374-83.
Smolenski C, Muff S, Smolenski-Kautz S. A Double-blind Comparative Trial of New Muscle Relaxant, Tizanidine (DS 103-282), and Baclofen in the Treatment of Chronic Spasticity in Multiple Sclerosis. Curr Med Res Opin. 1981;7(6):374-83. PubMed PMID: 7016449.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. AU - Smolenski,C, AU - Muff,S, AU - Smolenski-Kautz,S, PY - 1981/1/1/pubmed PY - 1981/1/1/medline PY - 1981/1/1/entrez SP - 374 EP - 83 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 7 IS - 6 N2 - A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis. Twenty-one hospitalized patients with stable spasticity participated in the 6-week trial. Eleven received tizanidine and 10 baclofen in gradually increasing daily doses. The optimal daily dose of tizanidine was between 8 and 36 mg and that of baclofen between 10 and 80 mg. Overall spastic state, spasms and clonus were similarly improved with both medications. In contrast, muscle strength, bladder function and the activities of daily living were more improved on tizanidine than on baclofen. Tiredness was the most frequent side-effect on tizanidine and muscle weakness on baclofen. The laboratory tests did not show any pathological changes with either medication. According to these results, tizanidine provides a new therapeutic alternative in the treatment of spasticity. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/7016449/A_double_blind_comparative_trial_of_new_muscle_relaxant_tizanidine__DS_103_282__and_baclofen_in_the_treatment_of_chronic_spasticity_in_multiple_sclerosis_ L2 - http://www.diseaseinfosearch.org/result/4969 DB - PRIME DP - Unbound Medicine ER -